Pfizer (PFE) Stock Offer, Spinoff Report Sees Fundamental Break-Up Post Zoetis (ZTS); Remember Bristol Myers & Mead Johnson? Business Wire NEW YORK & LONDON -- June 19, 2013 400m shares are due to hit the market and today’s the last day for tendering Pfizer (PFE) common shares in exchange for Zoetis (ZTS) stock. Further, with over 20% upside seen in the next year for both PFE and ZTS, an even bigger catalyst awaits smart investors in terms of a larger restructuring Spinoff from PFE in the coming years, according to UK independent and top proven research advisor on global special situations and break-ups, TSR (The Spinoff Report® / www.spinoffreport.com). TSR claim they’ve discovered the hidden fundamental catalysts and have equally added each to their client Model Portfolio holdings. These have notably outperformed the S&P500 by over 6x in 66 months. For TSR’s latest 32 page research, you can request it by clicking here. Speaking to Ryan Mendy of TSR, he comments, “Under the strong leadership of CEO, Ian Read (appointed in 2010 plus got his stock awards compensation tripled in 2011), PFE’s strategic desire to restructure its business portfolio has enhanced shareholder returns via the selloff of its nutrition business to Nestle SA for $12bn and now the separation of ZTS.” “Returning +106% in 5 years, PFE offers an attractive mix to investors of 1) inexpensive and discounted valuations, 2) a solid dividend and cash flow yield with limited earnings risk, 3) incentivized management, and 4) similar to Abbott Laboratories and its Spinoff, AbbVie (ABBV), the opportunity from the potential Spinoff of its innovative and value core businesses in 2016, which our research finds can unlock significant value for shareholders”, Mendy continued. Discounted Opportunity? PFE is offering shareholders a discount of 7% to the ZTS share price. For full analysis of the exchange offer, the potential selling/volatility and upside, click here Similar Exchange Offer: Bristol Myers Squibb (BMY)... Similar to the current PFE/ZTS exchange offer, Bristol Myers Squibb (BMY) had Split-off its 83% stake in the baby formula maker Mead Johnson (MJN) in November 2009, following an IPO of its 17% stake earlier in February 2009. Post IPO, MJN shares delivered a stunning return of 148% over the next twenty months. Akin to PFE’s exchange offer, BMY shareholders were able to exchange their shares for MJN shares, though at a slightly higher discount of 10%. Contact: The Spinoff Report® Ryan Mendy email@example.com +1-(212)-714-7046
Pfizer (PFE) Stock Offer, Spinoff Report Sees Fundamental Break-Up Post Zoetis (ZTS); Remember Bristol Myers & Mead Johnson?
Press spacebar to pause and continue. Press esc to stop.